Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 3Neoplasm Metastasis 3Colorectal Neoplasms 3Sarcoma, Ewing 2Ovarian Neoplasms 2Carcinoid Tumor 2Breast Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lymphoma 1Insulin-Like Growth Factor I, Resistance To 1Hemangiosarcoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Askin Tumor 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × ganitumab × Clear all
NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Dana-Farber Cancer Institute

Phase 2 Terminated
10 enrolled 15 charts
Sarcoma

Recurrence, Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡